Johnson & Johnson is slated to offer a preview of its surgical robotics solution strategy in May during its Medical Device Business Review Day in New York.
Johnson & Johnson is offering a preview of its surgical robotics strategy May 13th during its Medical Device Business Review Day in New York. Executives of the New Brunswick, NJ-based company announced the date during a call discussing its 4Q19 results on Wednesday.
Alex Gorsky, J&J’s CEO noted that going forward surgical robotics would be a driving force behind the company’s medtech division.
“As it relates to medical devices, we’ve been, I think, very consistent in sharing our thinking that, again, this next generation is certainly about the robotics component that helps facilitate perhaps having more consistency in an exact procedure, perhaps getting into a tighter space, having better access,” Gorsky said, according to a Seeking Alpha transcript of the earnings call.
The news follows the healthcare giant buying out Verily’s interest in the Verb Surgical joint venture for an undisclosed sum. The Verb buyout is one of two major developments that occurred last year that are set to power J&J’s upcoming surgical robotics platform. The second development is J&J’s acquisition of Auris Health.
Redwood City, CA-based Auris Health develops robotic technologies that have been focused on lung cancer. The firm has the Monarch Platform, an FDA-cleared system currently used in bronchoscopic diagnostic and therapeutic procedures.
Gorsky spoke about how both Verb and Auris play into the May 13th preview.
“We think combining Auris and Verb really helps ensure that we have a very strong role in the next-generation of the digital surgery platform and ongoing development,” Gorsky said according to a Seeking Alpha transcript of the earnings call. “Our teams are working now together in a really comprehensive way.
Image Credit: Omar Ford / MD+DI